| 6alpha-hydroxy Paclitaxel is a primary metabolite of the anticancer compound paclitaxel (Item No. 10461), produced by the action of the cytochrome P450 isoform CYP2C8.1,2 The generation of 6alpha-hydroxy paclitaxel by CYP2C8 can be impacted by other drugs (e.g., fluvastatin, Item No. 10010334) or dietary components that interefere with CYP2C8 activity, as well as by CYP2C8 genetic polymorphisms.3,4,5 Synonyms: betaS-(benzoylamino)-alphaR-hydroxy-(2aR,3S,4R,4aS,6R,9S,11S,12S,12aR,12bS,)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-3,4,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester-benzenepropanoic acid CAS Number: 153212-75-0 Molecular Formula: C47H51NO15 Molecular Weight: 869.91 Appearance: Crystalline solid Purity: 95% Solubility: Soluble in DMSO at 30mg/ml, in water at 1mg/ml and Methanol at 10mg/ml. Storage and Stability: May be stored at -20C. Stable for 6 months after receipt at -20C. Reconstitute with solvent. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures. |
